Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Start-Up Quarterly Statistics regular column feature image

Biopharmaceutical start-up financings declined 17% from $3.44bn in the first quarter to $2.84bn in the second quarter, according to Strategic Transactions. However, young drug developers continue to bring in large venture capital rounds, including SpringWorks Therapeutics Inc. and Fusion Pharmaceuticals Inc., which each raised more than $100m in separate series B rounds.

Alliances with and acquisitions of start-ups (companies operating for four years or less) also are bringing in big money, including a kidney disease-focused alliance between Goldfinch Bio Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business